[CAS NO. 119478-56-7] Meropenemtrihydrate

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [119478-56-7]

Catalog

HY-13678A

Brand

MCE

CAS

119478-56-7

DESCRIPTION [119478-56-7]

Overview

MDL	MFCD08600005
Molecular Weight	437.51
Molecular Formula	C17H31N3O8S
SMILES	O=C(C(N12)=C(S[C@@H]3CN[C@H](C(N(C)C)=O)C3)[C@H](C)[C@]2([H])[C@@H]([C@H](O)C)C1=O)O.O.O.O

For research use only. We do not sell to patients.

8 Publications Citing Use of MCE

Summary

Meropenem trihydrate (SM 7338 trihydrate) is a carbapenem antibiotic with broad-spectrum antibacterial activity. Meropenem trihydrate has activity against susceptible and resistant N. gonorrhoeae (MIC value of 0.02-0.06 mg/mL), H. influenzae (MIC value of 0.03-0.12 mg/mL), and H. ducreyi (MIC value of 0.015-0.12 mg/mL) ^[1] ^[2] .

In Vitro

Meropenem is intrinsically stable to dehydropeptidase-1 (DHP-1) degradation and Meropenem acts by inhibiting bacterial cell wall synthesis by binding to and inactivating penicillin-binding proteins (PBPs). Meropenem possesses broad-spectrum in vitro activity, which includes activity against many Gram-positive, Gram-negative and anaerobic bacteria; Meropenem lacks activity against Enterococcus faecium, methicillin-resistant Staphylococcus aureus and Stenotrophomonas maltophilia ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Meropenem (60 mg/kg; intraperitoneal injection; once; SD rats) treatment significantly reduces the incidence of pancreatic infection ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats (250-350 g) induced acute necrotizing pancreatitis ^[3]
Dosage:	60 mg/kg
Administration:	Intraperitoneal injection; once
Result:	Significantly reduced the incidence of pancreatic infection.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00752219	Pfizer	Complicated Intra-abdominal Infections	March 31, 2009	Phase 2
NCT01044719	Imperial College London	Cystic Fibrosis	January 2010	Phase 4
NCT05058105	Qilu Pharmaceutical Co., Ltd.	Healthy	October 8, 2020	Phase 1
NCT01429259	Joseph Kuti\|Thrasher Research Fund\|Hartford Hospital	Cystic Fibrosis\|Pneumonia\|Pseudomonas Aeruginosa Infection	February 2012	Phase 4
NCT03136796	University Hospital Hradec Kralove	Critical Illness	May 2, 2017
NCT02506686	Huashan Hospital	Central Nervous System Infections	September 2008	Phase 4
NCT02463747	Tel-Aviv Sourasky Medical Center	Fever\|Febrile Neutropenia	June 2015	Phase 4
NCT03174184	Johns Hopkins University	Tuberculosis, Pulmonary	August 23, 2017	Phase 2
NCT04629378	TASK Applied Science	Tuberculosis	August 17, 2020	Phase 2
NCT05578586	Oslo University Hospital	Drug Effect	December 14, 2021	Not Applicable
NCT03970265	Ludwig-Maximilians - University of Munich	Lung Transplantation	August 15, 2019
NCT05426499	Poznan University of Medical Sciences\|University at Buffalo\|The Greater Poland Cancer Centre	Population Modeling of Anti-infective Drugs	October 1, 2021
NCT02142751	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla\|Spanish Network for Research in Infectious Diseases	Infection Due to ESBL Escherichia Coli	July 2014	Phase 3
NCT03182504	Hoffmann-La Roche	Gram-negative Bacterial Infections	June 15, 2017	Phase 1
NCT04478721	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla\|Spanish Network for Research in Infectious Diseases\|SCReN Spanish research Network- CTU-HUVR	Bacteremia	December 15, 2020	Phase 3
NCT02213796	Sutep Jaruratanasirikul\|Prince of Songkla University	Initial Phase of Severe Sepsis and Septic Shock	January 2013	Phase 4
NCT05134298	Karolinska University Hospital	Antibiotic Pharmacokinetics	November 1, 2019
NCT01158937	Unity Health Toronto\|Sunnybrook Health Sciences Centre\|University of Toronto	Cystic Fibrosis Pulmonary Exacerbation	May 2010	Not Applicable
NCT05393505	The University of Hong Kong\|Queen Mary Hospital, Hong Kong	Neutropenic Fever	October 24, 2022	Phase 4
NCT03858387	Prince of Songkla University	Critical Illness\|Bacterial Infections	September 1, 2018
NCT01297842	Mahidol University	Drug Safety	May 2011	Phase 4
NCT03230838	Merck Sharp & Dohme LLC	Complicated Urinary Tract Infection\|Pyelonephritis	April 26, 2018	Phase 2
NCT00318994	Pfizer	Pancreatitis	February 2002	Phase 4
NCT03344627	Mahidol University	Sepsis\|Septic Shock\|Critical Illness\|Carbapenem\|Pharmacokinetic\|Pharmacodynamic\|Clinical Outcome\|Organ Failure, Multiple\|Morality	November 27, 2017	Not Applicable
NCT02475733	Pfizer	Complicated Intra-abdominal Infections	August 1, 2015	Phase 2
NCT03217136	Merck Sharp & Dohme LLC	Complicated Intra-Abdominal Infection	April 3, 2018	Phase 2
NCT02788240	Institute of Liver and Biliary Sciences, India	Acute on Chronic Liver Failure	May 1, 2016	Not Applicable
NCT01445678	Cubist Pharmaceuticals LLC	Complicated Intra-abdominal Infection	December 23, 2011	Phase 3
NCT04771884	Shandong University\|Children´s Hospital of Chongqing Medical University	Bacterial Meningitis\|Augmented Renal Clearance	October 1, 2020
NCT03671967	Rambam Health Care Campus\|Rabin Medical Center\|University of Modena and Reggio Emilia\|Tel Aviv Medical Center\|Meir Medical Center\|Soroka University Medical Center\|The Chaim Sheba Medical Center\|McGill University Health Centre+Research Institute of the McGill University Health Centre\|Jewish General Hospital\|Canadian Institutes of Health Research (CIHR)\|Hadassah Medical Organization	Beta Lactam Resistant Bacterial Infection\|Enterobacteriaceae Infections\|Bacteremia	May 1, 2019	Phase 4
NCT00307099	National Institute of Allergy and Infectious Diseases (NIAID)	Bacterial Infection	October 2006	Phase 3
NCT02047773	University of Edinburgh\|NHS Lothian	Bronchiectasis	January 2014	Phase 4
NCT04370145	Tongji Hospital\|Shanghai Children´s Hospital	Cholangitis, Secondary Biliary\|Treatment Compliance\|Antibodies Drug Specific	May 1, 2021	Phase 4
NCT02176122	The University of Queensland\|International Society of Chemotherapy\|Australian Society for Antimicrobials\|Queensland Clinical Trials & Biostatistics Centre\|Australasian Society for Infectious Diseases	Bloodstream Infections	February 2014	Phase 4
NCT01551394	PENTA Foundation\|Chiesi Farmaceutici S.p.A.	Sepsis	September 2012	Phase 3
NCT03507751	Medical University of Lublin\|University of Warmia and Mazury in Olsztyn	Infection\|Renal Failure	April 2, 2018
NCT01667094	The Alfred	Cystic Fibrosis	September 2012	Phase 4
NCT04238390	The University of Queensland\|Merck Sharp & Dohme LLC	Bacteremia Caused by Gram-Negative Bacteria	January 2022	Phase 3
NCT03452839	Università Vita-Salute San Raffaele	Antibiotic Resistant Infection\|Critical Illness	June 5, 2018	Phase 4
NCT02437045	The University of Queensland	Bloodstream Infections	April 2015	Phase 4
NCT00579956	University of Oxford\|Mahidol University\|Wellcome Trust	Melioidosis	December 2007	Not Applicable
NCT01147640	Cubist Pharmaceuticals LLC	Complicated Intra-abdominal Infection	June 25, 2010	Phase 2
NCT05340530	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Infections	April 2022	Phase 1
NCT02609646	Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva	Critical Illness\|Infection	January 2016
NCT00771316	Merck Sharp & Dohme LLC	Urinary Tract Infections	December 2008	Phase 3
NCT02486627	Achaogen, Inc.	Complicated Urinary Tract Infection\|Acute Pyelonephritis	January 11, 2016	Phase 3
NCT04816968	Ospedale San Carlo Borromeo\|Associazione Oncologica Milanese AmoLaVita ONLUS	Severe Bacterial Infections	September 2021	Phase 1
NCT01992198	Erzhen Chen\|RenJi Hospital\|Ruijin Hospital	Pancreatitis,Acute Necrotizing	July 2012	Phase 4
NCT03036826	University Hospital Tuebingen	Acute Kidney Insufficiency\|Anti-Infective Agent Toxicity	June 2019
NCT02349841	TASK Applied Science\|Eduardo Mondlane University\|GlaxoSmithKline\|Barcelona Centre for International Health Research\|Research Center Borstel	Pulmonary Tuberculosis	September 2014	Phase 2
NCT04132115	Azienda Sanitaria-Universitaria Integrata di Udine	Therapeutic Drug Monitoring\|Subarachnoid Hemorrhage\|Intracerebral Hemorrhage	October 1, 2019
NCT05392634	N.N. Petrov National Medical Research Center of Oncology\|The Foundation for Cancer Research Support (RakFond)	Bladder Cancer	February 2, 2022	Phase 3
NCT01570192	University of Florida	Bacterial Pneumonia	September 2010	Phase 2
NCT02615041	Sutep Jaruratanasirikul\|Prince of Songkla University	Ventilator-Associated Pneumonia	January 2004	Phase 4
NCT05204368	Sinovent Pty Ltd.	Complicated Urinary Tract Infection Including Acute Pyelonephritis	March 2022	Phase 3
NCT00534287	Kompetenznetz Sepsis\|AstraZeneca\|Bayer	Severe Sepsis\|Septic Shock	October 2007	Phase 3
NCT00435305	University Hospital Tuebingen	Pneumonia\|Bacteremia	November 2006
NCT00462878	PETHEMA Foundation	Allogenic Blood Stem Cell Transplantation\|Febrile Neutropenia	November 2002
NCT04154722	Ziauddin University	Typhoid Fever	June 20, 2019	Phase 4
NCT04489459	Al-Azhar University	Treatment of Blood Stream Infections Due to Multidrug-Resistant Klebsiella Pneumoniae	September 21, 2019	Phase 4
NCT01499290	Pfizer\|Forest Laboratories	Complicated Intra-Abdominal Infection	March 2012	Phase 3
NCT00061438	Pfizer	Pancreatitis, Acute Necrotizing	February 2003	Phase 4
NCT02149329	Amsterdam UMC, location VUmc\|ZonMw: The Netherlands Organisation for Health Research and Development\|FondsNutsOhra	Febrile Neutropenia\|Hematological Malignancy	December 2014	Phase 4
NCT01597973	University of Michigan	Pneumonia\|Blood Stream Infection	October 6, 2012	Phase 3
NCT02820987	Centre Hospitalier Universitaire de Besancon	Septic Shock	September 1, 2016	Phase 3
NCT02732327	Forest Laboratories	Neoplasms\|Febrile Neutropenia	May 17, 2016	Phase 2
NCT00619710	Pfizer	Skin Infection\|Abscess\|Cellulitis	February 2001	Phase 3
NCT03140826	University Hospital Tuebingen\|University Hospital of Cologne	Antibiotic Selection Pressure	January 30, 2018
NCT01726023	Pfizer	Complicated Intra-abdominal Infection	January 2013	Phase 3
NCT03032380	Shionogi\|Shionogi Inc.	Healthcare-associated Pneumonia (HCAP)\|Hospital Acquired Pneumonia (HAP)\|Ventilator Associated Pneumonia (VAP)	October 24, 2017	Phase 3
NCT03157388	University of Aarhus	Alcoholic Hepatitis	June 1, 2017	Not Applicable
NCT04402359	King Abdul Aziz Specialist Hospital	Ventilator Associated Pneumonia	July 5, 2018
NCT03174795	Hoffmann-La Roche	Urinary Tract Infections	July 11, 2017	Phase 1
NCT01970371	Achaogen, Inc.\|Department of Health and Human Services	Bloodstream Infections (BSI) Due to CRE\|Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE\|Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE\|Complicated Urinary Tract Infection (cUTI) Due to CRE\|Acute Pyelonephritis (AP) Due to CRE	September 16, 2014	Phase 3
NCT02784704	Tetraphase Pharmaceuticals, Inc.\|La Jolla Pharmaceutical Company	Complicated Intra-abdominal Infections\|Complicated Appendicitis	October 13, 2016	Phase 3
NCT01554124	PENTA Foundation\|Chiesi Farmaceutici S.p.A.	Meningitis	February 2013	Phase 1\|Phase 2
NCT04876430	Hospital de Clinicas de Porto Alegre\|Conselho Nacional de Desenvolvimento Científico e Tecnológico	Carbapenem-Resistant Enterobacteriaceae Infection\|Bloodstream Infection	May 4, 2021	Phase 2\|Phase 3
NCT03019965	Coordinación de Investigación en Salud, Mexico\|Instituto Mexicano del Seguro Social\|Hospital Infantil de Mexico Federico Gomez\|Hospital Regional de Alta Especialidad del Bajio	Sepsis	February 1, 2017	Not Applicable
NCT04553367	King Abdul Aziz Specialist Hospital	ARDS\|Septic Shock	July 2, 2020	Phase 1\|Phase 2
NCT05042271	Prince of Songkla University	Autoimmune Diseases	January 1, 2020
NCT03645668	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	Sepsis	January 30, 2018	Phase 4
NCT03891433	Universidad del Norte	Urinary Tract Infections\|Enterobacteriaceae Infections\|Infection Due to ESBL Bacteria\|Carbapenem\|Escherichia Coli Infection\|Klebsiella Pneumoniae Infection\|Clinical Trial\|Drug Resistance, Bacterial	April 1, 2019	Phase 4
NCT04233996	Hospital Universitari de Bellvitge\|Institut d´Investigació Biomèdica de Bellvitge\|Instituto de Salud Carlos III	Febrile Neutropenia	June 5, 2019	Phase 4
NCT02212392	Benazir Bhutto Hospital, Rawalpindi	Acute Pancreatitis	January 2013	Phase 1\|Phase 2
NCT03543436	Assistance Publique - Hôpitaux de Paris\|Groupe Hospitalier Paris Saint Joseph\|French National Network of Clinical Research in Infectious Diseases (RENARCI)	Urinary Tract Infections	January 4, 2019	Phase 3
NCT01808092	Pfizer	Nosocomial Pneumonia (NP)\|Ventilator-associated Pneumonia (VAP)	April 2013	Phase 3
NCT05565222	Assistance Publique - Hôpitaux de Paris	Sepsis\|Septic Shock	January 2023	Phase 3
NCT00438269	Canadian Critical Care Trials Group\|The Physicians´ Services Incorporated Foundation	Nosocomial Infection\|Pneumonia\|Systemic Inflammatory Response Syndrome\|Critical Illness\|Pyrexia	February 2003	Phase 2
NCT05355350	Rambam Health Care Campus\|The Chaim Sheba Medical Center\|Rabin Medical Center\|Hadassah Medical Organization	Beta Lactam Resistant Bacterial Infection\|Enterobacteriaceae Infections\|Bacteremia	July 1, 2022	Phase 4
NCT01732250	Mical Paul\|European Commission\|Rabin Medical Center	Gram-Negative Bacterial Infections	March 2013	Phase 4
NCT00891423	Austin Health	Sepsis	April 2009	Not Applicable
NCT00621192	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\|The Emmes Company, LLC	Necrotizing Enterocolitis\|Intra-abdominal Infection	June 2008	Phase 1\|Phase 2
NCT01944319	Qingtao Zhou\|Peking University Third Hospital	Lower Respiratory Tract Infection	July 2013	Phase 4
NCT01110382	Janssen Research & Development, LLC	Abscess, Intra-Abdominal\|Abdominal Abscess\|Abdomen, Acute\|Abdominal Pain\|Appendicitis\|Rupture\|Infection\|Intestinal Perforation\|Peritonitis\|Ileus	December 2010	Phase 3
NCT03477422	Venus Remedies Limited	Urinary Tract Infection Complicated\|Acute Pyelonephritis	January 11, 2014	Phase 3
NCT03571711	Hannover Medical School	Peritonitis Bacterial\|Liver Cirrhosis	June 28, 2018
NCT02972255	Hoffmann-La Roche	Healthy Volunteers	October 31, 2016	Phase 1
NCT00153634	Seattle Children´s Hospital\|Cystic Fibrosis Foundation	Cystic Fibrosis\|Chronic Bronchitis	March 2004	Not Applicable
NCT03485950	M.D. Anderson Cancer Center\|Merck Sharp & Dohme LLC\|National Cancer Institute (NCI)	Other Infectious Diseases	May 16, 2018	Phase 2
NCT02456974	University Hospital, Ghent\|University Hospital, Antwerp\|Queen Fabiola Children´s University Hospital, Brussels	Pharmacokinetics\|Amoxicillin-clavulanate\|Piperacillin-tazobactam\|Vancomycin\|Teicoplanin\|Meropenem\|Ciprofloxacin\|Amikacin	May 2012
NCT04979806	Wockhardt\|Medpace, Inc.	Complicated Urinary Tract Infection\|Acute Pyelonephritis	August 28, 2022	Phase 3
NCT03830333	Merck Sharp & Dohme LLC	Complicated Intra-abdominal Infections	March 20, 2019	Phase 3
NCT02070757	Cubist Pharmaceuticals LLC	Healthcare-Associated Pneumonia\|Ventilator-Associated Pneumonia\|Lung Diseases	September 2, 2014	Phase 3
NCT02840136	University Ghent\|King Baudouin Foundation\|Belgische Vereniging voor Strijd tegen Mucoviscidose	Cystic Fibrosis	February 2016	Not Applicable
NCT01381562	GlaxoSmithKline	Infections, Intestinal	October 3, 2011	Phase 2
NCT03840148	Venatorx Pharmaceuticals, Inc.	Urinary Tract Infections\|Acute Pyelonephritis	August 7, 2019	Phase 3
NCT05226923	Sumitovant Biopharma, Inc.	Bacterial Infections	January 12, 2022	Phase 1
NCT00318552	Pfizer	Sepsis	January 2002	Phase 4
NCT03630081	Wockhardt\|Medpace Finland OY	Complicated Urinary Tract Infection\|Acute Pyelonephritis	August 25, 2019	Phase 3
NCT01292031	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla\|European Commission	Ventilator-associated Bacterial Pneumonia	May 2012	Phase 3
NCT04257838	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	Sepsis\|Septic Shock	February 15, 2020
NCT04671589	Mabaret Al-Asafara Hospitals	Drug Toxicity	June 2021	Phase 4
NCT04555798	Mohamed Gaber Allam\|King Abdul Aziz Specialist Hospital	Patients With Respiratory Failure and Shocked	February 1, 2022	Phase 1\|Phase 2
NCT01455246	University of Padova	Cirrhosis\|Ascites\|Nosocomial Spontaneous Bacterial Peritonitis	October 2010	Phase 2\|Phase 3
NCT04983901	M.D. Anderson Cancer Center\|Merck Sharp & Dohme LLC	Hematopoietic and Lymphoid Cell Neoplasm\|Malignant Solid Neoplasm	September 14, 2021	Phase 2
NCT03717350	Hellenic Institute for the Study of Sepsis	Sepsis	October 27, 2018	Phase 2\|Phase 3
NCT05105035	Arrevus Inc.\|Aceragen	Melioidosis	June 14, 2022	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 228.57 mM ; Need ultrasonic)

H ₂ O : 12.5 mg/mL ( 28.57 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2857 mL	11.4283 mL	22.8566 mL
5 mM	0.4571 mL	2.2857 mL	4.5713 mL
10 mM	0.2286 mL	1.1428 mL	2.2857 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 100 mg/mL (228.57 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (5.71 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (5.71 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (5.71 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[(3S,5S)-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, hydrate (1:3), (4R,5S,6S)-

1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, trihydrate, [4R-[3(3S*,5S*),4α,5β,6β(R*)]]-

1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[(3S,5S)-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, trihydrate, (4R,5S,6S)-

Meropenem trihydrate